Validation of the SCALE-CryoAF risk model to predict very late return of atrial fibrillation after cryoballoon ablation.


Journal

Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing
ISSN: 1572-8595
Titre abrégé: J Interv Card Electrophysiol
Pays: Netherlands
ID NLM: 9708966

Informations de publication

Date de publication:
Nov 2023
Historique:
received: 20 12 2022
accepted: 25 01 2023
medline: 23 10 2023
pubmed: 9 2 2023
entrez: 8 2 2023
Statut: ppublish

Résumé

To date, few risk models have been validated to predict recurrent atrial fibrillation (AF) >1 year after ablation. The SCALE-CryoAF score was previously derived to predict very late return of AF (VLRAF) >1 year following cryoballoon ablation (CBA), with strong predictive ability. In this study, we aim to validate the SCALE-CryoAF score for VLRAF after CBA in a novel patient cohort. Retrospective analysis of a prospectively maintained single-center database was performed. Inclusion criteria were pulmonary vein isolation using CBA 2017-2020. Exclusion criteria included prior ablation, <1-year follow-up, lack of pre-CBA echocardiogram, additional ablation lesion sets, and documented AF recurrence 90-365 days post-CBA. The area under the curve (AUC) of SCALE-CryoAF was compared to the derivation value and other established risk models. Among 469 CBA performed, 241 (61% male, 62.8 ±11.7 years old) cases were included in analysis. There were 37 (15.4%) patients who developed VLRAF. Patients with VLRAF had a higher SCALE-CryoAF score (VLRAF 5.4 ± 2.7; no VLRAF 3.1 ± 2.9; p<0.001). SCALE-CryoAF was linearly associated with VLRAF (y=14.35x-11.72, R The current analysis validates the ability of SCALE-CryoAF to predict VLRAF after CBA in a novel patient cohort. Patients with a high SCALE-CryoAF score should be monitored closely for recurrent AF >1 year following CBA.

Sections du résumé

BACKGROUND BACKGROUND
To date, few risk models have been validated to predict recurrent atrial fibrillation (AF) >1 year after ablation. The SCALE-CryoAF score was previously derived to predict very late return of AF (VLRAF) >1 year following cryoballoon ablation (CBA), with strong predictive ability. In this study, we aim to validate the SCALE-CryoAF score for VLRAF after CBA in a novel patient cohort.
METHODS METHODS
Retrospective analysis of a prospectively maintained single-center database was performed. Inclusion criteria were pulmonary vein isolation using CBA 2017-2020. Exclusion criteria included prior ablation, <1-year follow-up, lack of pre-CBA echocardiogram, additional ablation lesion sets, and documented AF recurrence 90-365 days post-CBA. The area under the curve (AUC) of SCALE-CryoAF was compared to the derivation value and other established risk models.
RESULTS RESULTS
Among 469 CBA performed, 241 (61% male, 62.8 ±11.7 years old) cases were included in analysis. There were 37 (15.4%) patients who developed VLRAF. Patients with VLRAF had a higher SCALE-CryoAF score (VLRAF 5.4 ± 2.7; no VLRAF 3.1 ± 2.9; p<0.001). SCALE-CryoAF was linearly associated with VLRAF (y=14.35x-11.72, R
CONCLUSIONS CONCLUSIONS
The current analysis validates the ability of SCALE-CryoAF to predict VLRAF after CBA in a novel patient cohort. Patients with a high SCALE-CryoAF score should be monitored closely for recurrent AF >1 year following CBA.

Identifiants

pubmed: 36754907
doi: 10.1007/s10840-023-01494-z
pii: 10.1007/s10840-023-01494-z
pmc: PMC9908502
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1859-1865

Subventions

Organisme : NCATS NIH HHS
ID : KL2 TR001424
Pays : United States
Organisme : NHLBI NIH HHS
ID : R35 HL161249
Pays : United States

Informations de copyright

© 2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Références

Xu J, Luc JG, Phan K. Atrial fibrillation: review of current treatment strategies. J Thorac Dis. 2016;8(9):E886–900. https://doi.org/10.21037/jtd.2016.09.13 .
doi: 10.21037/jtd.2016.09.13 pubmed: 27747025 pmcid: 5059277
January CT, Wann LS, Calkins H, Chen LY, Cigarroa JE, Cleveland JC Jr, et al. 2019 AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2019;74(1):104–32. https://doi.org/10.1016/j.jacc.2019.01.011 .
doi: 10.1016/j.jacc.2019.01.011 pubmed: 30703431
January CT, Wann LS, Alpert JS, Calkins H, Cigarroa JE, Cleveland JC Jr, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. Circulation. 2014;130(23):2071–104. https://doi.org/10.1161/CIR.0000000000000040 .
doi: 10.1161/CIR.0000000000000040 pubmed: 24682348
Andrade JG, Deyell MW, Macle L, Wells GA, Bennett M, Essebag V, et al. Progression of atrial fibrillation after cryoablation or drug therapy. N Engl J Med. 2022;388:105–16. https://doi.org/10.1056/NEJMoa2212540 .
doi: 10.1056/NEJMoa2212540 pubmed: 36342178
Andrade JG, Deyell MW, Verma A, Macle L, Khairy P. The cryoballoon vs irrigated radiofrequency catheter ablation (CIRCA-DOSE) study results in context. Arrhythm Electrophysiol Rev. 2020;9(1):34–9. https://doi.org/10.15420/aer.2019.13 .
doi: 10.15420/aer.2019.13 pubmed: 32637118 pmcid: 7330729
Knight BP, Novak PG, Sangrigoli R, Champagne J, Dubuc M, Adler SW, et al. Long-term outcomes after ablation for paroxysmal atrial fibrillation using the second-generation cryoballoon: final results from STOP AF post-approval study. JACC Clin Electrophysiol. 2019;5(3):306–14. https://doi.org/10.1016/j.jacep.2018.11.006 .
doi: 10.1016/j.jacep.2018.11.006 pubmed: 30898232
Ganesan AN, Shipp NJ, Brooks AG, Kuklik P, Lau DH, Lim HS, et al. Long-term outcomes of catheter ablation of atrial fibrillation: a systematic review and meta-analysis. J Am Heart Assoc. 2013;2(2):e004549. https://doi.org/10.1161/JAHA.112.004549 .
doi: 10.1161/JAHA.112.004549 pubmed: 23537812 pmcid: 3647286
Kuck KH, Furnkranz A, Chun KR, Metzner A, Ouyang F, Schluter M, et al. Cryoballoon or radiofrequency ablation for symptomatic paroxysmal atrial fibrillation: reintervention, rehospitalization, and quality-of-life outcomes in the FIRE AND ICE trial. Eur Heart J. 2016;37(38):2858–65. https://doi.org/10.1093/eurheartj/ehw285 .
doi: 10.1093/eurheartj/ehw285 pubmed: 27381589 pmcid: 5070448
Wasserlauf J, Pelchovitz DJ, Rhyner J, Verma N, Bohn M, Li Z, et al. Cryoballoon versus radiofrequency catheter ablation for paroxysmal atrial fibrillation. Pacing Clin Electrophysiol. 2015;38(4):483–9. https://doi.org/10.1111/pace.12582 .
doi: 10.1111/pace.12582 pubmed: 25627795
Kirchhof P, Camm AJ, Goette A, Brandes A, Eckardt L, Elvan A, et al. Early Rhythm-Control Therapy in Patients with Atrial Fibrillation. N Engl J Med. 2020;383(14):1305–16. https://doi.org/10.1056/NEJMoa2019422 .
doi: 10.1056/NEJMoa2019422 pubmed: 32865375
Vogt J, Heintze J, Gutleben KJ, Muntean B, Horstkotte D, Nolker G. Long-term outcomes after cryoballoon pulmonary vein isolation: results from a prospective study in 605 patients. J Am Coll Cardiol. 2013;61(16):1707–12. https://doi.org/10.1016/j.jacc.2012.09.033 .
doi: 10.1016/j.jacc.2012.09.033 pubmed: 23199518
Mujovic N, Marinkovic M, Markovic N, Shantsila A, Lip GY, Potpara TS. Prediction of very late arrhythmia recurrence after radiofrequency catheter ablation of atrial fibrillation: The MB-LATER clinical score. Sci Rep. 2017;7:40828. https://doi.org/10.1038/srep40828 .
doi: 10.1038/srep40828 pubmed: 28106147 pmcid: 5247745
Peigh G, Kaplan RM, Bavishi A, Diaz CL, Baman JR, Matiasz R, et al. A novel risk model for very late return of atrial fibrillation beyond 1 year after cryoballoon ablation: the SCALE-CryoAF score. J Interv Card Electrophysiol. 2020;58(2):209–17. https://doi.org/10.1007/s10840-019-00588-x .
doi: 10.1007/s10840-019-00588-x pubmed: 31327104
Peigh G, Wasserlauf J, Vogel K, Kaplan RM, Pfenniger A, Marks D, et al. Impact of pre-ablation weight loss on the success of catheter ablation for atrial fibrillation. J Cardiovasc Electrophysiol. 2021;32(8):2097–104. https://doi.org/10.1111/jce.15141 .
doi: 10.1111/jce.15141 pubmed: 34191371 pmcid: 9305992
Kornej J, Hindricks G, Shoemaker MB, Husser D, Arya A, Sommer P, et al. The APPLE score: a novel and simple score for the prediction of rhythm outcomes after catheter ablation of atrial fibrillation. Clin Res Cardiol. 2015;104(10):871–6. https://doi.org/10.1007/s00392-015-0856-x .
doi: 10.1007/s00392-015-0856-x pubmed: 25876528 pmcid: 4726453
Jacobs V, May HT, Bair TL, Crandall BG, Cutler M, Day JD, et al. The impact of risk score (CHADS2 versus CHA2DS2-VASc) on long-term outcomes after atrial fibrillation ablation. Heart Rhythm. 2015;12(4):681–6. https://doi.org/10.1016/j.hrthm.2014.12.034 .
doi: 10.1016/j.hrthm.2014.12.034 pubmed: 25546809
Canpolat U, Aytemir K, Yorgun H, Sahiner L, Kaya EB, Oto A. A proposal for a new scoring system in the prediction of catheter ablation outcomes: promising results from the Turkish Cryoablation Registry. Int J Cardiol. 2013;169(3):201–6. https://doi.org/10.1016/j.ijcard.2013.08.097 .
doi: 10.1016/j.ijcard.2013.08.097 pubmed: 24063932
Akkaya E, Berkowitsch A, Greiss H, Hamm CW, Sperzel J, Neumann T, et al. PLAAF score as a novel predictor of long-term outcome after second-generation cryoballoon pulmonary vein isolation. Europace. 2018;20(FI_3):f436–f43. https://doi.org/10.1093/europace/eux295 .
doi: 10.1093/europace/eux295 pubmed: 29161372
Kornej J, Hindricks G, Arya A, Sommer P, Husser D, Bollmann A. The APPLE score - a novel score for the prediction of rhythm outcomes after repeat catheter ablation of atrial fibrillation. PLoS One. 2017;12(1):e0169933. https://doi.org/10.1371/journal.pone.0169933 .
doi: 10.1371/journal.pone.0169933 pubmed: 28085921 pmcid: 5235369
Wojcik M, Berkowitsch A, Zaltsberg S, Hamm CW, Pitschner HF, Kuniss M, et al. Score associated with the outcome after multiple ablation procedures in patients with atrial fibrillation. Pacing Clin Electrophysiol. 2014;37(6):682–90. https://doi.org/10.1111/pace.12356 .
doi: 10.1111/pace.12356 pubmed: 24499345
Jastrzebski M, Kielbasa G, Fijorek K, Bednarski A, Kusiak A, Sondej T, et al. Comparison of six risk scores for the prediction of atrial fibrillation recurrence after cryoballoon-based ablation and development of a simplified method, the 0-1-2 PL score. J Arrhythm. 2021;37(4):956–64. https://doi.org/10.1002/joa3.12557 .
doi: 10.1002/joa3.12557 pubmed: 34386122 pmcid: 8339100
Calkins H, Hindricks G, Cappato R, Kim YH, Saad EB, Aguinaga L, et al. 2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation: executive summary. J Arrhythm. 2017;33(5):369–409. https://doi.org/10.1016/j.joa.2017.08.001 .
doi: 10.1016/j.joa.2017.08.001 pubmed: 29021841 pmcid: 5634725
Lizewska-Springer A, Dabrowska-Kugacka A, Lewicka E, Drelich L, Krolak T, Raczak G. Echocardiographic predictors of atrial fibrillation recurrence after catheter ablation: a literature review. Cardiol J. 2020;27(6):848–56. https://doi.org/10.5603/CJ.a2018.0067 .
doi: 10.5603/CJ.a2018.0067 pubmed: 29924375 pmcid: 8079104

Auteurs

Tanvi Nayak (T)

Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.

Graham Peigh (G)

Division of Cardiology, Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.

Alexandru B Chicos (AB)

Division of Cardiology, Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.

Rishi Arora (R)

Division of Cardiology, Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.

Susan Kim (S)

Division of Cardiology, Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.

Albert Lin (A)

Division of Cardiology, Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.

Nishant Verma (N)

Division of Cardiology, Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.

Anna Pfenniger (A)

Division of Cardiology, Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.

Kaustubha D Patil (KD)

Division of Cardiology, Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.

Bradley P Knight (BP)

Division of Cardiology, Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.

Rod S Passman (RS)

Division of Cardiology, Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA. rod.passman@nm.org.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH